Synamics Therapeutics ApS: Financial statements 2024
CVR: 44258048
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Synamics Therapeutics ApS (CVR 44258048) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -1,694,760 and a net result of DKK -1,554,274. Equity in the 2024 report amounted to DKK 472,772. The solvency ratio was 13.3%.
- Gross Profit
- DKK -1,694,760
- Profit/Loss
- DKK -1,554,274
- Equity
- DKK 472,772
- Total Assets
- DKK 3,549,533
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of July 9, 2024, Per Falholt has joined the board of directors of Synamics Therapeutics ApS.
As of July 9, 2024, Helder Takashi Imoto Nakaya has left the board of directors of Synamics Therapeutics ApS.
Synamics Therapeutics ApS has published its interim report for the period August 24, 2023 to December 31, 2023.
About Synamics Therapeutics ApS
Synamics Therapeutics ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Violet Zahedi. The board consists of Aaron Daniel Capar (chair), Albert Jelke Kooistra, Per Falholt and Violet Zahedi. The company is owned by Synamics Therapeutics Inc.. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK 129,466 and a net result of DKK -588,453 compared with DKK -1,554,274 the year before. Equity in the 2025 report amounted to DKK -114,946.
